Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Nomizo, Takashi ^a   Ozasa, Hiroaki ^a   Tsuji, Takahiro ^a   Funazo, Tomoko ^a   Yasuda, Yuto ^a   Yoshida, Hironori ^a   Yagi, Yoshitaka ^a   Sakamori, Yuichi ^a   Nagai, Hiroki ^a   Hirai, Toyohiro ^a   Kim, Young Hak ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ALLELE; CANCER STAGING; FEMALE; GENETICS; GENOTYPE; HUMAN; KAPLAN MEIER METHOD; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; NON SMALL CELL LUNG CANCER; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME;

EID: 85016135829     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep45124     Document Type: Article

References (43)

1. Siegel, R., Miller, K. & Jemal, A. Cancer statistics, 2015. CA Cancer J Clin 65, 29 (2015).
2. Borghaei, H. et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N. Engl. J. Med. 373, 1627-39 (2015).
3. Brahmer, J. et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N. Engl. J. Med. 373, 123-35 (2015).
4. Gettinger, S. N. et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol. 33, 2004-2012 (2015).
5. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12, 252-264 (2012).
6. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-7 (2014).
7. Sorensen, S. F. et al. PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy. Transl. Oncol. 9, 64-69 (2016).
8. Chae, Y. K. et al. Biomarkers for PD-1/PD-L1 Blockade Terapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection? Clin. Lung Cancer 17, 350-361 (2016).
9. Akbay, E. A. et al. Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors. Cancer Discov. 3, 1355-1363 (2013).
10. Rizvi, N. A. et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung c ancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16, 257-65 (2015).
11. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
12. Postow, M. a. et al. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. N. Engl. J. Med. 372, 2006-2017 (2015).
13. Champiat, S., Ferté, C., Lebel-binay, S., Eggermont, A. & Soria, J. Exomics and immunogenics Bridging mutational load and immune checkpoints efcacy. Oncoimmunology 3, e2781 (2014).
14. Nicolazzo, C. et al. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Sci. Rep. 6, 31726 (2016).
15. Dulak, A. M. et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifes recurrent driver events and mutational complexity. Nat Genet 45, 478-486 (2013).
16. Findlay, J. M., Middleton, M. R. & Tomlinson, I. A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage. Ann. Oncol. 26, 624-44 (2015).
17. Isla, D. et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol. 15, 1194-1203 (2004).
18. Queirolo, P. et al. Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study. Cancer Invest. 31, 336-345 (2013).
19. Breunis, W. B. et al. Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade. J. Immunother. 31, 586-590 (2008).
20. Oko, A. et al. CD52 Gene Polymorphism and its Potential Effect on The Response To Alemtuzumab In Renal Transplant Recipients. Ann Acad Med Stetin 55, 22-26 (2009).
21. Fabris, M. et al. The CC homozygosis of the-174G>C IL-6 polymorphism predicts a lower efcacy of rituximab therapy in rheumatoid arthritis. Autoimmun. Rev. 11, 315-320 (2012).
22. Racila, E. et al. A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Terapy of Follicular Lymphoma. Clin. Cancer Res. 14 (2008).
23. Lin, T. S. Ofatumumab: a novel monoclonal anti-CD20 antibody. Pharmgenomics. Pers. Med. 3, 51-9 (2010).
24. Mitchell, A. L. et al. Programmed death ligand 1 (PD-L1) gene variants contribute to autoimmune Addison's disease and graves' disease susceptibility. J. Clin. Endocrinol. Metab. 94, 5139-5145 (2009).
25. Wang, W. et al. A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma. Hum. Genet. 132, 641-648 (2013).
26. Ma, Y. et al. Polymorphisms of co-inhibitory molecules (CTLA-4/PD-1/PD-L1) and the risk of non-small cell lung cancer in a Chinese population. Int. J. Clin. Exp. Med. 8, 16585-91 (2015).
27. Pizarro, C. et al. PD-L1 gene polymorphisms and low serum level of PD-L1 protein are associated to type 1 diabetes in Chile. Diabetes. Metab. Res. Rev. 30, 761-766 (2014).
28. Lee, S. Y. et al. PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with frst-line paclitaxel-cisplatin chemotherapy. Sci. Rep. 6, 25952 (2016).
29. Kerr, K. M. et al. Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? J. Torac. Oncol. 10, 985-989 (2015).
30. Abdel-Rahman, O. Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis. Crit. Rev. Oncol. Hematol. 101, 75-85 (2016).
31. Gainor, J. F. et al. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer (NSCLC): A Retrospective Analysis. Clin. Cancer Res. 22, 4585-4593 (2016).
32. Gong, A.-Y. et al. MicroRNA-513 Regulates B7-H1 Translation and Is Involved in IFN-Induced B7-H1 Expression in Cholangiocytes. J. Immunol. 182, 1325-1333 (2009).
33. Shi, X.-L. et al. Counter-regulation of rejection activity against human liver grafs by donor PD-L1 and recipient PD-1 interaction. J. Hepatol. 64, 1274-1282 (2016).
34. Kataoka, K. et al. Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers. Nature 534, 402-406 (2016).
35. Willimsky, G. et al. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J. Exp. Med. 205, 1687-1700 (2008).
36. Chen, D. S. et al. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin. Cancer Res. 18, 6580-7 (2012).
37. Nishimura, H., Nose, M., Hiai, H., Minato, N. & Honjo, T. Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor. Immunity 11, 141-151 (1999).
38. Nishimura, H. et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-defcient mice. Science 291, 319-22 (2001).
39. Hayashi, M., Kouki, T., Takasu, N., Sunagawa, S. & Komiya, I. Association of an A/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves' disease in Japanese patients. Eur. J. Endocrinol. 158, 817-822 (2008).
40. Ni, R. et al. PD-1 gene haplotype is associated with the development of type 1 diabetes mellitus in Japanese children. Hum. Genet. 121, 223-232 (2007).
41. Prokunina, L. et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat. Genet. 32, 666-669 (2002).
42. Savabkar, S., Azimzadeh, P., Chaleshi, V., Nazemalhosseini Mojarad, E. & Asadzadeh Aghdaei, H. Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with gastric cancer. Gastroenterol. Hepatol. from Bed to Bench 6, 178-182 (2013).
43. Abelson, A. K. et al. No evidence of association between genetic variants of the PDCD1 ligands and SLE. Genes Immun. 8, 69-74 (2007).